UBS AM’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-65,734
| Closed | -$223K | – | 2861 |
|
|
2018
Q3 | $223K | Hold |
65,734
| – | – | ﹤0.01% | 2403 |
|
|
2018
Q2 | $247K | Hold |
65,734
| – | – | ﹤0.01% | 2383 |
|
|
2018
Q1 | $269K | Buy |
65,734
+21,100
| +47% | +$98.3K | ﹤0.01% | 2257 |
|
|
2017
Q4 | $208K | Buy |
44,634
+5,577
| +14% | +$30.7K | ﹤0.01% | 2301 |
|
|
2017
Q3 | $277K | Buy |
39,057
+741
| +2% | +$5.33K | ﹤0.01% | 2113 |
|
|
2017
Q2 | $277K | Buy |
38,316
+102
| +0.3% | +$637 | ﹤0.01% | 2072 |
|
|
2017
Q1 | $235K | Hold |
38,214
| – | – | ﹤0.01% | 2110 |
|
|
2016
Q4 | $224K | Sell |
38,214
-35,500
| -48% | -$194K | ﹤0.01% | 2073 |
|
|
2016
Q3 | $391K | Hold |
73,714
| – | – | ﹤0.01% | 2121 |
|
|
2016
Q2 | $488K | Sell |
73,714
-5,986
| -8% | -$33.5K | ﹤0.01% | 1967 |
|
|
2016
Q1 | $372K | Sell |
79,700
-6,500
| -8% | -$25.9K | ﹤0.01% | 2098 |
|
|
2015
Q4 | $435K | Sell |
86,200
-1,202,181
| -93% | -$5.71M | ﹤0.01% | 2130 |
|
|
2015
Q3 | $4.54M | Sell |
1,288,381
-641,718
| -33% | -$4.3M | 0.01% | 1089 |
|
|
2015
Q2 | $19.3M | Buy |
1,930,099
+82,603
| +4% | +$886K | 0.02% | 730 |
|
|
2015
Q1 | $23.5M | Buy |
1,847,496
+794,100
| +75% | +$10.2M | 0.02% | 660 |
|
|
2014
Q4 | $14.9M | Buy |
1,053,396
+33,500
| +3% | +$519K | 0.01% | 772 |
|
|
2014
Q3 | $14M | Sell |
1,019,896
-257,200
| -20% | -$3.94M | 0.01% | 763 |
|
|
2014
Q2 | $19.6M | Buy |
1,277,096
+50,200
| +4% | +$712K | 0.02% | 686 |
|
|
2014
Q1 | $20.9M | Buy |
1,226,896
+669,196
| +120% | +$10.1M | 0.02% | 657 |
|
|
2013
Q4 | $7.22M | Buy |
557,700
+533,700
| +2,224% | +$6.37M | 0.01% | 918 |
|
|
2013
Q3 | $242K | Hold |
24,000
| – | – | ﹤0.01% | 2218 |
|
|
2013
Q2 | $179K | Buy |
+24,000
| New | +$188K | ﹤0.01% | 2296 |
|
UBS AM's KERX Position: Q4 2018 in Review
UBS AM sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 65,734 shares — an estimated $223K sold.
UBS AM first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $23.5M in Q1 2015. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- UBS AM reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- UBS AM sold 65,734 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $223K.
- UBS AM first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- UBS AM's Keryx Biopharmaceuticals Inc position peaked at $23.5M in Q1 2015.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on UBS AM's 13F filing for Q4 2018, filed 13 Feb 2019.